Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215


Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.


Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.


Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.


Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.


Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.

Cancer Immunol Res. 2015 Sep;3(9):1063-9. doi: 10.1158/2326-6066.CIR-15-0006. Epub 2015 May 5.


Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.


Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.


Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.

J Clin Oncol. 2006 Jul 1;24(19):3089-94.


Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators.

Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.


A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R.

Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4.


The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.

Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.

Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review.


Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.


Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.


Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun 24.


Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB.

J Urol. 2011 Sep;186(3):877-81. doi: 10.1016/j.juro.2011.04.070. Epub 2011 Jul 23.


Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Huber ML, Haynes L, Parker C, Iversen P.

J Natl Cancer Inst. 2012 Feb 22;104(4):273-9. doi: 10.1093/jnci/djr514. Epub 2012 Jan 9.


Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL.

Cancer Immunol Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 3.


Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.


Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.


Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

Supplemental Content

Support Center